Journals / Turkish Journal of Pharmaceutical Sciences / 2022 / Cilt: 19 - Sayı: 1

Resveratrol Delivery via Gene Therapy: Entering the Modern Era

Gen Terapisi Yoluyla Resveratrol İletimi: Modern Çağa Girme

Pages
104–109
Publication Date
2022-11-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review is to provide a holistic view of the development of resveratrol gene treatment as a powerful option to treat various deadly diseases

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Resveratrol is a natural compound (an antioxidant) and exhibits numerous therapeutic activities.
📊
Key Findings & Data:From a pharmacokinetic perspective, it is unclear whether resveratrol targets the site of action after oral administration because of quick metabolism and excretion that creates doubt on the biological application of the high doses characteristically used for clinical trials.
💡
Conclusion & Impact:This review is to provide a holistic view of the development of resveratrol gene treatment as a powerful option to treat various deadly diseases
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Resveratrol is a natural compound (an antioxidant) and exhibits numerous therapeutic activities. From a pharmacokinetic perspective, it is unclear whether resveratrol targets the site of action after oral administration because of quick metabolism and excretion that creates doubt on the biological application of the high doses characteristically used for clinical trials. However, these limitations act as a barrier and a challenge for the development of new delivery systems. Recently, gene delivery offers various advantages and has provided treatment options for diseases that are beyond the reach of traditional approaches. The objective of gene therapy for genetic diseases is to achieve durable expression of the therapeutic gene at a level sufficient to alleviate or cure disease symptoms with minimal adverse events. The perception of the molecular and cellular mechanisms steering to therapy and vector-related hindrances have caused in the progress of extremely complex gene delivery with enhanced protection and effectiveness. With the help of gene therapy, it could be possible to target the delivery of resveratrol directly into the host cells and bypass its pharmacokinetic limitations and enhancement of its therapeutic effect. This review is to provide a holistic view of the development of resveratrol gene treatment as a powerful option to treat various deadly diseases

Özet

Resveratrol, doğal bir bileşiktir (bir antioksidan) ve çok sayıda terapötik aktivite sergiler. Farmakokinetik bir perspektiften, resveratrolün, klinik deneyler için karakteristik olarak kullanılan yüksek dozlarının biyolojik uygulamasında şüphe yaratan hızlı metabolizma ve atılım nedeniyle oral uygulamadan sonra etki alanını hedefleyip hedeflemediği açık değildir. Bununla birlikte, bu sınırlamalar, yeni dağıtım sistemlerinin geliştirilmesi için bir engel ve zorluk teşkil etmektedir. Son zamanlarda, gen dağıtımının çeşitli avantajlar sağladığı ve geleneksel yaklaşımların ulaşamayacağı hastalıklar için tedavi seçenekleri sağladığı görülmüştür. Genetik hastalıklar için gen terapisinin amacı, minimum yan etki ile hastalık semptomlarını iyileştirmek veya iyileştirmek için yeterli bir seviyede terapötik genin kalıcı ifadesini elde etmektir. Tedaviye yönlendiren moleküler ve hücresel mekanizmaların algılanması ve vektöre bağlı engeller, gelişmiş koruma ve etkililik ile aşırı derecede karmaşık gen dağıtımının ilerlemesine neden olmuştur. Gen terapisinin yardımıyla, resveratrolün doğrudan konakçı hücrelere verilmesini hedeflemek ve farmakokinetik sınırlamalarını ve terapötik etkisinin arttırılmasını atlamak mümkün olabilir. Bu derleme, çeşitli ölümcül hastalıkları tedavi etmek için güçlü bir seçenek olarak resveratrol gen tedavisinin gelişiminin bütünsel bir görünümünü sağlamaktır.

🔖

Cite This Article

SINGH, G. (2022). Resveratrol Delivery via Gene Therapy: Entering the Modern Era. Turkish Journal of Pharmaceutical Sciences, Cilt: 19 - Sayı: 1, 104–109. https://ajindex.com/articles/613600

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Takaoka MJ. Of the phenolic substances of white hellebore (Veratrumgrandiflorum Loes. fil). J Faculty Sci Hokkaido Im Univ. 1940;3:1-16
  2. Singh G, Pai RS. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS. J Control Release. 2014;194:178-188
  3. Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58:1428-1447
  4. Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019;20:904
  5. Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR. Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1. AIDS. 2014;28:317- 323
  6. James JS. Resveratrol: why it matters in HIV. AIDS Treat News. 2006:3-5
  7. Chimento A, De Amicis F, Sirianni R, Sinicropi MS, Puoci F, Casaburi I, Saturnino C, Pezzi V. Progress to improve oral bioavailability and beneficial effects of resveratrol. Int J Mol Sci. 2019;20:1381
  8. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9-15
  9. Gambini J, López-Grueso R, Olaso-González G, Inglés M, Abdelazid K, Alami MEL, Bonet-Costa V, Borrás C, Viña J. Resveratrol: distribution, properties and perspectives. Rev Esp Geriatr Gerontol. 2013;48:79-88
  10. Neves AR, Lúcio M, Martins S, Lima JL, Reis S. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine. 2013;8:177-187. 11. https://www.fda.gov/regulatory-information/search-fda-guidance- documents/considerations-design-early-phase-clinical-trials-cellular- and-gene-therapy-products (Accessed date: 24/05/2020)
  11. Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273-288
  12. Long Term Follow-Up After Administration of Human Gene Therapy Products; Draft Guidance for Industry, July 2018. (Accessed date: 24/05/2020). 14. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy- products/what-gene-therapy#footnote1 (Accessed date: 24/05/2020). 15. https://ghr.nlm.nih.gov/primer/therapy/genetherapy (Accessed date: 24/05/2020)
  13. Kaufmann KB, Büning H, Galy A, Schambach A, Grez M. Gene therapy on the move. EMBO Mol Med. 2013;5:1642-1661
  14. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene 2013;525:162-169
  15. Brody H. Ge